AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
25 mars 2024 08h30 HE
|
Landos Biopharma, Inc.
NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement...
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
21 mars 2024 08h00 HE
|
Landos Biopharma, Inc.
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK,...
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
08 janv. 2024 08h00 HE
|
Landos Biopharma, Inc.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
21 nov. 2023 08h00 HE
|
Landos Biopharma, Inc.
NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS...
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
09 nov. 2023 08h00 HE
|
Landos Biopharma, Inc.
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW...
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
23 oct. 2023 08h00 HE
|
Landos Biopharma, Inc.
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress
19 sept. 2023 08h00 HE
|
Landos Biopharma, Inc.
NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial...
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells
14 sept. 2023 08h00 HE
|
Landos Biopharma, Inc.
NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
09 août 2023 08h00 HE
|
Landos Biopharma, Inc.
Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of...
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
31 mai 2023 16h15 HE
|
Landos Biopharma, Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...